抑郁障碍与心脑血管疾病共病多学科诊疗指南
Multidisciplinary clinical practice guideline for the diagnosis and treatment of depressive disorder comorbid with cardiovascular and cerebrovascular diseases
-
摘要: 基于循证医学证据,针对抑郁障碍与心脑血管疾病(cardiovascular and cerebrovascular diseases, CCVD)双向关联的复杂临床现状,构建多学科协作的两者共病规范化诊疗指南。由来自精神医学、心血管病学、心理学、公共卫生及循证医学等相关学科的42名专家参与专家函询。采用人群、干预、对照和结局(population, intervention, comparison, and outcomes, PICO)原则确立临床问题。系统检索中英文权威数据库(截至2025年6月),运用推荐分级的评估、制定与评价(grading of recommendations assessment, development, and evaluation, GRADE)体系进行证据确定性分级和推荐强度评定。通过两轮改良德尔菲法函询及无记名投票确定核心临床问题,评估各专业的相关证据,审阅初稿并提出推荐意见。指南形成10条核心推荐意见,包括4个方面。(1)筛查与评估:推荐在诊疗初期进行基线代谢指标监测及患者健康问卷9(patient health questionnaire-9, PHQ-9)量表筛查。(2)抗抑郁药物:强推荐心血管安全性良好的选择性5-羟色胺再摄取抑制剂(selective serotonin reuptake inhibitor, SSRI;如艾司西酞普兰)为一线治疗;弱推荐使用5-羟色胺-去甲肾上腺素再摄取抑制剂(serotonin- norepinephrine reuptake inhibitor, SNRI; 如度洛西汀、文拉法辛),需动态监测血压;强不推荐使用心脏不良反应显著的三环类抗抑郁药(tricyclic antidepressant, TCA)。(3)非药物干预:强推荐认知行为疗法(cognitive behavioral therapy, CBT)、正念疗法及生活方式管理;弱推荐重复经颅磁刺激(repetitive transcranial magnetic stimulation, rTMS)及有氧运动。(4)综合管理:强调在CCVD常规治疗基础上,积极防控药物间相互作用引起的出血风险或心律失常。本指南强调多学科协作及个体化综合干预,旨在优化抑郁障碍与CCVD共病的临床决策流程,改善患者的社会功能与长期预后。Abstract: Based on evidence-based medicine, this guideline aims to construct a multidisciplinary and standardized diagnostic and treatment framework for the complex bidirectional relationship between depressive disorder and cardiovascular and cerebrovascular diseases (CCVD). A total of 42 experts from psychiatry, cardiology, psychology, public health and evidence-based medicine participated in the consensus process. Clinical questions were formulated according to the population, intervention, comparison, and outcomes (PICO) principle. The grading of recommendations assessment, development, and evaluation (GRADE) system was employed for evidence certainty grading and recommendation strength evaluation, with consensus reached through two rounds of the modified Delphi method and anonymous voting. The guideline provides 10 core recommendations including 4 aspects. (1) Screening and assessment: baseline metabolic monitoring and patient health questionnaire-9 (PHQ-9) screening are recommended at the initial point of care. (2) antidepressants: selective serotonin reuptake inhibitors (SSRI) with favorable cardiovascular safety such as escitalopram are strongly recommended as first-line treatment; serotonin–norepinephrine reuptake inhibitors (SNRI) such as duloxetine and venlafaxine are weakly recommended with dynamic blood pressure monitoring; tricyclic antidepressants (TCA) with significant cardiac side effects are strongly not recommended. (3) Non-pharmacological interventions: cognitive behavioral therapy (CBT), mindfulness-based therapy, and lifestyle management are strongly recommended; repetitive transcranial magnetic stimulation (rTMS) and aerobic exercise are weakly recommended. (4) Comprehensive management: the prevention of drug interactions causing bleeding or arrhythmia within routine CCVD care is emphasized. This guide emphasizes that multidisciplinary collaboration and individualized interventions are essential to optimizing clinical decision-making and improving the social functioning and long-term prognosis of these patients.
下载: